

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 15 JANUARY 2025

The board of directors (the “**Board**”) of Sinopharm Tech Holdings Limited (the “**Company**”) is pleased to announce that at the annual general meeting of the Company held on 15 January 2025 (the “**AGM**”), all proposed resolutions (the “**Resolutions**”) as set out in the notice of the AGM dated 24 December 2024 were duly passed by the shareholders of the Company by way of poll. All directors of the Company, except for Dr. CHENG Yanjie and Mr. HEUNG Pik Lun, attended the AGM in person or by electronic means.

The poll results in respect of all the Resolutions are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive and consider the audited consolidated financial statements, the directors’ report and independent auditors’ report of the Company for the year ended 30 June 2024	450,308,120 (100.00%)	0 (0.00%)
2.	a. To re-elect Mr. HO Kam Kin as an executive director	450,308,120 (100.00%)	0 (0.00%)
	b. To re-elect Ms. KWOK Shuk Yi as an executive director	450,308,120 (100.00%)	0 (0.00%)
	c. To authorize the Board to fix the directors’ remuneration	450,308,120 (100.00%)	0 (0.00%)
3.	To re-appoint SFAI (HK) CPA Limited as auditors of the Company and to authorize the Board to fix their remuneration	450,308,120 (100.00%)	0 (0.00%)

4.	To grant a general mandate to the directors to issue, allot and otherwise deal with the shares of the Company	450,308,120 (100.00%)	0 (0.00%)
5.	To grant a general mandate to the directors to repurchase the shares of the Company	450,308,120 (100.00%)	0 (0.00%)
6.	To add the total number of the shares repurchased by the Company to the mandate granted to the directors under resolution no. 4	450,308,120 (100.00%)	0 (0.00%)

As more than 50% of the votes were cast in favour of each of the ordinary resolutions, all the ordinary resolutions were duly passed at the AGM.

The shareholders of the Company who are entitled to attend and vote at the AGM is determined by the register of members of the Company at the close of the business day on 14 January 2025.

As at the date of the AGM, the issued share capital of the Company comprised 633,693,055 ordinary shares entitling the shareholders of the Company to attend and vote on the Resolutions at the AGM. No shareholder was entitled to attend and abstain from voting in favour of the Resolutions at the AGM as set out in Rule 17.47A of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and no shareholder was required under the GEM Listing Rules to abstain from voting.

SFAI (HK) CPA Limited, the auditor of the Company, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

“Scope of work of SFAI (HK) CPA Limited

The poll results were subject to scrutiny by SFAI (HK) CPA Limited (“SFAI Hong Kong”), Certified Public Accountants, whose work was limited to certain procedures requested by the Company to agree the poll results summary prepared by the Company to poll forms collected and provided by the Company to SFAI Hong Kong. The work performed by SFAI Hong Kong in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants nor did it include provision of any assurance or advice on matters of legal interpretation or entitlement to vote.”

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
HO Kam Kin
Executive Director

Hong Kong, 15 January 2025

As at the date of this announcement, the Board comprises Mr. HO Kam Kin and Ms. KWOK Shuk Yi as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence, Mr.

HSU Dong An and Mr. HEUNG Pik Lun as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at <https://www.hkexnews.hk> for a minimum period of 7 days from the date of its publication and on the website of the Company at <http://www.sinopharmtech.com.hk>.